DoMore Diagnostics appoints Anders Tuv to Board of Directors
OSLO – December 4, 2025 – DoMore Diagnostics, a leader in AI precision medicine for cancer, is pleased to announce that Anders Tuv has been appointed to its Board of Directors, effective immediately.
Anders Tuv brings to DoMore Diagnostics a distinguished career in life-science investment, technology development and international business leadership. As Managing Director at Radforsk Invest, he has helped drive the growth of companies advancing immunotherapies, precision medicines and diagnostics.
Together with his experience founding and advising innovative biotech ventures, Andres Tuv’s appointment aligns strongly with DoMore Diagnostics’ strategic focus on advancing its digital biomarkers for personalized cancer care and accelerating global commercialization.
“We are honoured to welcome Anders to our Board,” said Tomas N. Alme, Chair of the Board at DoMore Diagnostics. “His deep sector expertise, proven track record in scaling life-science companies and global network will be invaluable as we move into our next phase of growth. Anders’ strategic perspective will help us further strengthen our position and deliver on our ambition to bring high-impact diagnostic tools to market.”
Anders Tuv added: “I am delighted to join the DoMore Diagnostics Board at such an exciting time. The company’s technology holds strong promise in transforming diagnostics and patient care. I look forward to working closely with the management team and fellow board members to accelerate progress, drive value and impact.”
Bio - Anders Tuv
Anders Tuv is Managing Director of Radforsk Invest, a life-science investment company focused on cutting-edge immunotherapies and precision medicines. A seasoned entrepreneur and investment professional, Anders has extensive experience in strategy, business development, global partnerships, M&A, IPOs, and fundraising across the healthcare and biotech sectors.
He has co-founded several life-science ventures, including Zelluna and ARTBIO, and previously chaired the boards of Nykode Therapeutics and OncoImmunity. He currently serves on the boards of Zelluna ASA, Aleap Ventures, Nextera AS, OnDosis AB, and ClexBio Inc.
Anders holds an MBE degree and has completed executive programs at INSEAD.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
DoMore Diagnostics has received funding from the European Innovation Council (EIC) Accelerator program.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Histotype Px is a registered trademark in the European Union. Trademark registration status may vary by country.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com